Absence of an effective high-throughput drug-screening system for Babesia parasites is considered one of the main causes for the presence of a wide gap in the treatment of animal babesiosis when compared with other hemoprotozoan diseases, such as malaria. Recently, a simple, accurate, and automatic fluorescence assay was established for large-scale anti-Babesia (B. bovis, B. bigemina, B. divergens, B. caballi and T. equi) drug screening. Such development will facilitate anti-Babesia drug discovery, especially in the post-genomic era, which will bring new chemotherapy targets with the completion of the Babesia genome sequencing project currently in progress. In this review, we present the current progress in the various assays for in vitro and in vivo anti-Babesia drug testing, as well as the challenges, highlighting new insights into the future of anti-Babesia drug screening.

中文翻译：

---

体外和体内抗巴贝虫药功效测试的测定方法：当前的进展，前景和挑战。

与其他血液原生动物疾病（例如疟疾）相比，缺乏有效的针对巴贝虫寄生虫的高通量药物筛查系统被认为是治疗动物巴贝病的主要原因之一。最近，建立了一种简单，准确，自动的荧光检测方法，用于大规模的抗巴贝斯病（牛双螺旋杆菌，双歧双歧杆菌，多形芽孢杆菌，卡巴利螺旋杆菌和马鞭毛虫）药物筛选。这种发展将促进抗巴贝虫病药物的发现，特别是在后基因组时代，随着目前正在进行的巴贝虫病基因组测序项目的完成，这将带来新的化学疗法靶标。在这篇评论中，我们介绍了针对体外和体内抗巴贝虫病药物测试的各种检测方法的最新进展，以及挑战，